These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35881304)

  • 21. The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies.
    Odinet JS; Day CE; Cruz JL; Heindel GA
    J Manag Care Spec Pharm; 2018 Oct; 24(10):952-959. PubMed ID: 30247100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis.
    Na H; Kwon SH; Son KH; Baek Y; Kim J; Lee EK
    BioDrugs; 2023 Mar; 37(2):205-218. PubMed ID: 36729329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence.
    Feagan BG; Marabani M; Wu JJ; Faccin F; Spronk C; Castañeda-Hernández G
    Adv Ther; 2020 Nov; 37(11):4491-4518. PubMed ID: 32910420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review.
    García-Beloso N; Altabás-González I; Samartín-Ucha M; Gayoso-Rey M; De Castro-Parga ML; Salgado-Barreira Á; Cibeira-Badia A; Piñeiro-Corrales MG; González-Vilas D; Pego-Reigosa JM; Martínez-López de Castro N
    Br J Clin Pharmacol; 2022 Feb; 88(4):1529-1550. PubMed ID: 34622969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.
    Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ
    Am J Clin Dermatol; 2020 Aug; 21(4):483-491. PubMed ID: 32048187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
    Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
    Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review.
    Bakalos G; Zintzaras E
    Clin Ther; 2019 Jan; 41(1):155-173.e13. PubMed ID: 30551802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of switching from two anti-TNF biosimilars back to biologic reference products in Germany
.
    Reuber K; Kostev K
    Int J Clin Pharmacol Ther; 2019 Jun; 57(6):323-328. PubMed ID: 30990409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding?
    Hung A; Vu Q; Mostovoy L
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1234-1244. PubMed ID: 29172975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P; Fiorino G; Danese S
    Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review.
    Leonard E; Wascovich M; Oskouei S; Gurz P; Carpenter D
    J Manag Care Spec Pharm; 2019 Jan; 25(1):102-112. PubMed ID: 30589628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence.
    Macaluso FS; Cummings JF; Atreya R; Choi J; Orlando A
    Expert Opin Biol Ther; 2022 Feb; 22(2):203-223. PubMed ID: 34314284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
    Lee S; Lee H; Kim E
    BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products.
    Moore TJ; Mouslim MC; Blunt JL; Alexander GC; Shermock KM
    JAMA Intern Med; 2021 Jan; 181(1):52-60. PubMed ID: 33031559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The design of clinical trials to support the switching and alternation of biosimilars.
    Faccin F; Tebbey P; Alexander E; Wang X; Cui L; Albuquerque T
    Expert Opin Biol Ther; 2016 Dec; 16(12):1445-1453. PubMed ID: 27666115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and Analysis of Biosimilar Switching Studies.
    Chow SC; Lee SJ
    Pharmaceut Med; 2019 Oct; 33(5):379-388. PubMed ID: 31933227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort.
    Gros B; Plevris N; Constantine-Cooke N; Lyons M; O'Hare C; Noble C; Arnott ID; Jones GR; Lees CW; Derikx LAAP
    United European Gastroenterol J; 2023 Mar; 11(2):179-188. PubMed ID: 36802176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are we ready to close the discussion on the interchangeability of biosimilars?
    Ebbers HC; Schellekens H
    Drug Discov Today; 2019 Oct; 24(10):1963-1967. PubMed ID: 31254488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epoetin biosimilars in Europe: five years on.
    Mikhail A; Farouk M
    Adv Ther; 2013 Jan; 30(1):28-40. PubMed ID: 23242745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biosimilars for the treatment of psoriasis.
    Puig L; López-Ferrer A
    Expert Opin Biol Ther; 2019 Oct; 19(10):993-1000. PubMed ID: 31237786
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.